278 天前 - … to afatinib and erlotinib. Moreover, PFS of patients with ECOG 0–1 treated with
gefitinib was significantly shorter than that of patients treated with afatinib or erlotinib. However, …

283 天前 - … It is noticed that many patients treated with gefitinib and erlotinib have mutations
in the EGFR-TK domain, which led to drug resistance. Since approximately half of the …

285 天前 - … in patients who have developed resistance to current therapies such as TKIs like
gefitinib or erlotinib. … However, almost all NSCLC patients who undergo treatment with first- or …

287 天前 - … Therefore, gefitinib may show greater tumor tissue penetration and … Asian patients
with advanced NSCLC. In our analysis, the superiority of afatinib over gefitinib and erlotinib …

292 天前 - … Within this cohort we identified 1109 patients, 654 (59%) with … ) patients were
diagnosed with baseline brain metastasis (BM). Patients were treated with gefitinib (19%), erlotinib …

297 天前 - … follow-up period for all patients was 26.6 months (range, … up periods among patients
who received gefitinib/erlotinib, … treatment (gefitinib, erlotinib, and afatinib) among patients …

300 天前 - … patients (28 males, 56 females), there were 82 patients with lung cancer and two
with colon cancer. Eighty-three patients … ) which mainly were gefitinib (n=56) and erlotinib (n=…

306 天前 - … First, the quinazoline scaffold of gefitinib (5) was utilized in a macrocyclization strategy
… such as gefitinib (5), erlotinib (6), afatinib, or dacomitinib for the treatment of NSCLC. But …

307 天前 - … treating patients with EGFR-mutated advanced lung adenocarcinoma and bone
metastases, we present the treatment outcomes of 3 patients … such as gefitinib, erlotinib, or …

309 天前 - … the patient from time of metastatic relapse. a The patient was commenced on imatinib
therapy … EGFR inhibition with osimertinib but not gefitinib or erlotinib was able to decrease …